Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.

Crose LE, Galindo KA, Kephart JG, Chen C, Fitamant J, Bardeesy N, Bentley RC, Galindo RL, Chi JT, Linardic CM.

J Clin Invest. 2014 Jan;124(1):285-96. doi: 10.1172/JCI67087. Epub 2013 Dec 16.

2.

Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

Ahn EH.

Anticancer Res. 2013 May;33(5):2029-35.

PMID:
23645752
3.

PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma.

Thalhammer V, Lopez-Garcia LA, Herrero-Martin D, Hecker R, Laubscher D, Gierisch ME, Wachtel M, Bode P, Nanni P, Blank B, Koscielniak E, Schäfer BW.

Cancer Res. 2015 Jan 1;75(1):98-110. doi: 10.1158/0008-5472.CAN-14-1246. Epub 2014 Nov 14.

4.

Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.

Kephart JJ, Tiller RG, Crose LE, Slemmons KK, Chen PH, Hinson AR, Bentley RC, Chi JT, Linardic CM.

Clin Cancer Res. 2015 Nov 1;21(21):4868-80. doi: 10.1158/1078-0432.CCR-14-1797. Epub 2015 Jun 12.

5.

Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.

Jothi M, Mal M, Keller C, Mal AK.

Mol Cancer Ther. 2013 Dec;12(12):2663-74. doi: 10.1158/1535-7163.MCT-13-0277. Epub 2013 Oct 9.

6.

PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.

Marshall AD, van der Ent MA, Grosveld GC.

Mol Carcinog. 2012 Oct;51(10):807-15. doi: 10.1002/mc.20848. Epub 2011 Aug 31.

PMID:
21882254
7.

PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis.

Marshall AD, Lagutina I, Grosveld GC.

Cancer Res. 2011 Dec 15;71(24):7471-80. doi: 10.1158/0008-5472.CAN-11-0924. Epub 2011 Oct 28.

8.

JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.

Walters ZS, Villarejo-Balcells B, Olmos D, Buist TW, Missiaglia E, Allen R, Al-Lazikani B, Garrett MD, Blagg J, Shipley J.

Oncogene. 2014 Feb 27;33(9):1148-57. doi: 10.1038/onc.2013.46. Epub 2013 Feb 25.

9.

The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).

Ciarapica R, De Salvo M, Carcarino E, Bracaglia G, Adesso L, Leoncini PP, Dall'Agnese A, Walters ZS, Verginelli F, De Sio L, Boldrini R, Inserra A, Bisogno G, Rosolen A, Alaggio R, Ferrari A, Collini P, Locatelli M, Stifani S, Screpanti I, Rutella S, Yu Q, Marquez VE, Shipley J, Valente S, Mai A, Miele L, Puri PL, Locatelli F, Palacios D, Rota R.

Oncogene. 2014 Aug 7;33(32):4173-84. doi: 10.1038/onc.2013.471. Epub 2013 Nov 11.

PMID:
24213577
10.

IRIZIO: a novel gene cooperating with PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS).

Picchione F, Pritchard C, Lagutina I, Janke L, Grosveld GC.

Carcinogenesis. 2011 Apr;32(4):452-61. doi: 10.1093/carcin/bgq273. Epub 2010 Dec 22.

11.

Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation.

Dietz KN, Miller PJ, Iyengar AS, Loupe JM, Hollenbach AD.

Int J Biochem Cell Biol. 2011 Jun;43(6):936-45. doi: 10.1016/j.biocel.2011.03.010. Epub 2011 Mar 31.

12.

Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.

Dietz KN, Miller PJ, Hollenbach AD.

Biochemistry. 2009 Dec 15;48(49):11786-95. doi: 10.1021/bi9012947.

13.

Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma.

Hu Q, Yuan Y, Wang C.

PLoS One. 2013 Jun 14;8(6):e68065. doi: 10.1371/journal.pone.0068065. Print 2013.

14.

The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.

Linardic CM, Naini S, Herndon JE 2nd, Kesserwan C, Qualman SJ, Counter CM.

Cancer Res. 2007 Jul 15;67(14):6691-9.

16.

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, Ponzetto C.

Cancer Res. 2006 May 1;66(9):4742-9.

17.

Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

Ahn EH, Mercado GE, Laé M, Ladanyi M.

Oncol Rep. 2013 Aug;30(2):968-78. doi: 10.3892/or.2013.2513. Epub 2013 Jun 3.

18.

FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM.

Clin Cancer Res. 2012 Jul 15;18(14):3780-90. doi: 10.1158/1078-0432.CCR-10-3063. Epub 2012 May 30.

19.
20.

Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease.

Lagutina IV, Valentine V, Picchione F, Harwood F, Valentine MB, Villarejo-Balcells B, Carvajal JJ, Grosveld GC.

PLoS Genet. 2015 Feb 6;11(2):e1004951. doi: 10.1371/journal.pgen.1004951. eCollection 2015.

Supplemental Content

Support Center